Phase II Study of isolated lung perfusion combined with pulmonary metastasectomy for the treatment of patients with operable lung metastases from colorectal carcinoma, osteosarcoma or soft tissue sarcoma.
Patient-derived models representing systemic relapse of soft tissue sarcoma to guide therapeutic decision making in metastatic patients
Onderzoek naar nieuwe behandelingsmethoden voor weke delen sarcomen - efficiëntie en toxiciteit van cytotoxische prodrugs en gerichte inhibitoren in xenograftmodellen
Cytotoxische therapie herzien: verkenning van innovatieve pro(drugs)in patiënt-afgeleide xenograft modellen van weke delen sarcoom
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 620
Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma The European Organisation for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG)
Eribulin mesylate (E7389) in patients with leiomyosarcoma (LMS) and other (OTH) subtypes of soft tissue sarcoma (STS): a Phase II study from the European Organisation for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group (EORTC 62052)
Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072
Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcoma